Aspen Pharmacare’s shares slid another 8% on Wednesday even as the group issued a statement clarifying certain aspects of its business to stem a sell-off. This means the company has lost more than a third of its value, or nearly R100 per share, since it released results for the year ended June on September 13 and said it would sell its nutritionals business for less than the market expected. A voluntary clarification announcement on Wednesday failed to arrest the decline, with the share closing at R173.23, the lowest it has been in more than five years. That compares to a close of R272.50 a week before. Aspen said it expected organic revenue growth of 1%-4% in its commercial pharmaceuticals business for the 2019 financial year. To allay concerns from some investors, it said it had no off-balance sheet funding in place and that all guarantees to financial institutions only applied to wholly owned subsidiaries. Its guarantees to financial institutions were R73.5bn, while reported borr...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, Morningstar financial data, and digital access to the Sunday Times and Times Select.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00.